← Back to Search

DNA Methyltransferase Inhibitor

SNDX-5613 + ASTX727 + Venetoclax for Acute Myeloid Leukemia

Phase 1 & 2
Recruiting
Led By Ghayas Issa, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study and at least 3 months after the last treatment
Patients must be receiving itraconazole, ketoconazole, posaconazole, or voriconazole (strong CYP3A4 inhibitors) for antifungal prophylaxis for at least 7 days prior to enrollment and while on SNDX-5613 treatment. Patients must not be receiving any other strong CYP3A4 inhibitors/inducers
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights

Study Summary

This trial is testing a new combination of drugs for leukemia.

Who is the study for?
This trial is for individuals aged 12 and older, weighing at least 40kg, with relapsed/refractory acute myeloid leukemia (AML) or mixed phenotype acute leukemia with a myeloid phenotype. Participants must have an ECOG performance status of ≤2, be on certain antifungal medications, and not be taking other strong CYP3A4 inhibitors/inducers. They should agree to contraception use during the study and for three months after. Exclusions include active malignancy under treatment, severe gastrointestinal/metabolic conditions affecting drug absorption, recent significant cardiovascular events, uncontrolled medical conditions or infections.Check my eligibility
What is being tested?
The trial is testing the highest tolerable dose of SNDX-5613 in combination with ASTX727 (decitabine/cedazuridine) and venetoclax in patients with AML or MPAL. The goal is to determine if this oral drug combination can control these types of leukemia effectively.See study design
What are the potential side effects?
Potential side effects may include digestive issues due to oral medication intake; blood disorders from bone marrow suppression; increased risk of infection; liver function abnormalities; heart problems such as arrhythmias or reduced heart function; fatigue from anemia or other causes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a male who is sterile or will use contraception during and 3 months after the study.
Select...
I am taking certain antifungal medications and no other strong medications that affect drug metabolism.
Select...
My leukemia has returned or is not responding to treatment.
Select...
I can take care of myself but might not be able to do heavy physical work.
Select...
I am 12 years or older and weigh at least 40kg.
Select...
My liver is functioning well, based on my bilirubin and AST/ALT levels.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To establish the recommended phase II dose (RP2D) of SNDX-5613 in combination with oral decitabine/cedazuridine (ASTX727) and venetoclax for patients with acute myeloid leukemia (AML).

Trial Design

3Treatment groups
Experimental Treatment
Group I: VenetoclaxExperimental Treatment1 Intervention
Tablets by mouth on Days 1-14 of each cycle.
Group II: SNDX-5613Experimental Treatment1 Intervention
Capsules by mouth 2 times every day (about 12 hours apart).
Group III: ASTX727Experimental Treatment1 Intervention
Tablets by mouth on Days 1-5 of each cycle.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Venetoclax
FDA approved
ASTX727
2018
Completed Phase 3
~240

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Syndax Pharmaceuticals, Inc.UNKNOWN
4 Previous Clinical Trials
132 Total Patients Enrolled
M.D. Anderson Cancer CenterLead Sponsor
2,972 Previous Clinical Trials
1,787,278 Total Patients Enrolled
Astex Pharmaceuticals, Inc.Industry Sponsor
95 Previous Clinical Trials
7,918 Total Patients Enrolled

Media Library

ASTX727 (DNA Methyltransferase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05360160 — Phase 1 & 2
Acute Myeloid Leukemia Research Study Groups: SNDX-5613, Venetoclax, ASTX727
Acute Myeloid Leukemia Clinical Trial 2023: ASTX727 Highlights & Side Effects. Trial Name: NCT05360160 — Phase 1 & 2
ASTX727 (DNA Methyltransferase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05360160 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are people still being recruited for this experiment?

"From what is stated on clinicaltrials.gov, this trial is still looking for participants. The listing was first put up on October 14th 2022 and has had no changes since then."

Answered by AI

How many people are able to enroll in this trial?

"The trial is recruiting for 43 patients across 1 locations."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
2022. "A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05360160.
~12 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top